HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J teeth-tinting mouthwash

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson Healthcare Products Division of McNeil re-launches its pre-brush mouth rinse Listerine Agent Cool Blue to help kids pay more attention to brushing their teeth by temporarily tinting their teeth blue, the Morris Plains, N.J.-based firm announces Sept. 29. The alcohol-free formula is for 6- to 12-year-olds and features an "enhanced preservative system" that includes potassium sorbate and cetylpyridinium chloride, a spokeswoman said. The re-launch comes more than a year after the product was recalled in April 2007 because "the preservative system was not adequate," J&J said. The new formula has "undergone rigorous quality standards" within FDA guidelines and meets "the highest safety standards," the spokeswoman added

You may also be interested in...

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments. 

Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed

Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts